1-苯甲酰哌嗪 | 13754-38-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-苯甲酰哌嗪
• 中文别名: 1-苯甲酰基哌嗪；1-苯酰甲基哌嗪；N-苯甲酰基哌嗪
• 英文名称: N-Benzoylpiperazine
• 英文别名: phenyl(piperazin-1-yl)methanone；1-benzoylpiperazine
• CAS: 13754-38-6
• 化学式: C₁₁H₁₄N₂O
• mdl: MFCD00810192
• 分子量: 190.245
• InChiKey: VUNXBQRNMNVUMV-UHFFFAOYSA-N

物化性质

• 熔点：
  61-64 °C (lit.)
• 沸点：
  145 °C/0.05 mmHg (lit.)
• 密度：
  1.115±0.06 g/cm3(Predicted)
• 溶解度：
  DMF：30 mg/ml； DMF:PBS(pH7.2)(1:2)：0.33mg/ml； DMSO：30 mg/ml；乙醇：30 mg/ml

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存放于惰性气体中，并避免接触湿气（特别是防潮）。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Benzoylpiperazine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Benzoylpiperazine
CAS number: 13754-38-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H14N2O
Molecular weight: 190.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

1-苯甲酰基哌嗪是一种生物化学试剂，可用于生物材料或有机化合物的研究，在生命科学领域中具有重要作用。

反应信息

• 作为反应物：
  描述：

  1-苯甲酰哌嗪 在 盐酸 、 tin 作用下， 以 氯仿 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 [4-(4-amino-phenyl)-piperazin-1-yl]-phenyl-methanone
  参考文献：
  名称：

  N- [4-（4-（烷基/芳基/杂芳基）-哌嗪-1-基）-苯基]-氨基甲酸乙酯衍生物的设计，合成及药理学评价

  摘要：

  一系列的烷基/芳基/杂芳基哌嗪衍生物（37 - 54），设计并作为潜在的抗惊厥药合成。目标化合物具有令人满意的物理化学和药代动力学特性。在最大电击（MES）和皮下戊四氮（sc-PTZ）癫痫发作试验中筛选了合成的化合物的体内抗惊厥活性。此外，使用旋转法进行神经毒性评估。结构活性关系研究表明，在哌嗪环上具有芳族基团的化合物显示出有效的抗惊厥活性。化合物多数表现抗MES活性，而化合物39，41，42，43，44，50，52，和53中都发作表现出测试抗惊厥活性。除了所有的化合物42，46，47，和50没有表现出神经毒性。活性最高的衍生物45在MES测试中显示出有效的抗惊厥活性，剂量为30 mg / kg（0.5 h）和100 mg / kg（4 h），并且在sc-PTZ测试中也具有出色的保护作用（100 mg / kg）在两个时间间隔。因此，化合物45在被广泛用于研究癫痫发生模型的PTZ癫痫发作模

  DOI：

  10.1016/j.bmcl.2015.01.004
• 作为产物：
  描述：

  (4-tert-butylpiperazin-1-yl)phenylmethanone 在 三氟乙酸 、 盐酸 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 0.5h， 以0.583 g的产率得到1-苯甲酰哌嗪
  参考文献：
  名称：

  取代邻羟基苯酮化合物在制备治疗神经变性 疾病药物中的应用

  摘要：

  本发明公开了一种取代邻羟基苯酮化合物或其在药学上可接受的盐在制备治疗神经变性疾病药物中的应用，其结构如式I所示，式I中，R1的结构式为R2的结构式独立地为‑NR8R9或者含有‑N的五元环、六元环或七元环；R3独立地选自H、羟基、胺基、C1‑C10烷基、C1‑C10烯基、芳基，或C1‑C10卤代烷基、C1‑C4氧杂烷基、C1‑C4氮杂烷基，或卤素；该类化合物不仅具有乙酰胆碱酯酶抑制活性，其水解产物还具有金属离子螯合作用，因而可以从多个靶点进行治疗，适合用于制备治疗神经变性疾病药物，特别适合用于治疗阿尔茨海默症或帕金森氏病，具有较好的神经变性疾病应用前景。

  公开号：

  CN108570022B
• 作为试剂：
  描述：

  1-(2-bromobenzenesulfonyl)-3-chloromethyl-1H-indole 在 1-苯甲酰哌嗪 作用下， 以 1,1-二氯乙烷 为溶剂， 反应 5.0h， 生成 {4-[1-(2-bromobenzenesulfonyl)-1H-indole-3-ylmethyl]piperazin-1-yl}phenylmethanone
  参考文献：
  名称：

  [EN] TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY
  [FR] INDOLES TETRACYCLIQUES 3-SUBSTITUES A AFFINITE POUR LE RECEPTEUR DE SEROTONINE

  摘要：

  本发明涉及新型取代四环3-取代吲哚，其通式表示为（I），其立体异构体、放射性同位素、N-氧化物、多晶型、药学上可接受的盐、药学上可接受的溶剂化合物、有用的生物活性代谢物以及上述任何合适的组合，以及制备通式（I）化合物、其立体异构体、放射性同位素、N-氧化物、多晶型、药学上可接受的盐、药学上可接受的溶剂化合物、有用的生物活性代谢物的过程，还包括上述任何合适的组合。

  公开号：

  WO2004055026A1

文献信息

• [EN] ANTIBODY-DRUG CONJUGATES AND THERAPEUTIC METHODS USING THE SAME<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT ET PROCÉDÉS THÉRAPEUTIQUES UTILISANT CEUX-CI
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD

  公开号：WO2018002902A1

  公开（公告）日：2018-01-04

  The invention discloses an antibody-drug conjugate of Formula (I): (I) Ab-[L-Dn]x wherein: Ab comprises a broadly neutralizing anti-HIV antibody; L comprises a linker molecule covalently bonded to said broadly neutralizing anti-HIV antibody; D comprises one or more drugs comprising an HIV therapeutic compound covalently bonded to said linker molecule L, wherein said one or more broadly neutralizing anti-HIV antibodies Ab specifically bind to an HIV envelope glycoprotein and said one or more drugs D specifically bind to an HIV envelope glycoprotein; n is selected from 1-4; and x is selected from 1-12.

  该发明公开了一种公式（I）的抗体药物偶联物：（I）Ab-[L-Dn]x，其中：Ab包括一种广谱中和抗HIV抗体；L包括与所述广谱中和抗HIV抗体共价结合的连接子分子；D包括与所述连接子分子L共价结合的一种或多种包含HIV治疗化合物的药物，其中所述一种或多种广谱中和抗HIV抗体Ab特异性地结合到HIV包膜糖蛋白，并且所述一种或多种药物D特异性地结合到HIV包膜糖蛋白；n选自1-4；x选自1-12。
• Synthesis of C4-Aminated Indoles via a Catellani and Retro-Diels–Alder Strategy
  作者：Bo-Sheng Zhang、Yuke Li、Zhe Zhang、Yang An、Yu-Hua Wen、Xue-Ya Gou、Si-Qi Quan、Xin-Gang Wang、Yong-Min Liang

  DOI：10.1021/jacs.9b05009

  日期：2019.6.19

  N-benzoyloxyamines, and norbornadiene. The Catellani and retro-Diels-Alder strategy was used in this domino process. o-Iodoaniline, with electron-donating and sterically hindered protecting groups, made the reaction selective toward o-C-H amination. On the basis of density functional theory calculations, the intramolecular Buchwald coupling of this reaction underwent a dearomatization and a 1,3-palladium migration

  通过邻碘苯胺、N-苯甲酰氧基胺和降冰片二烯的三组分交叉偶联合成了高度官能化的 4-氨基吲哚。在这个多米诺骨牌过程中使用了 Catellani 和复古 Diels-Alder 策略。邻碘苯胺具有供电子和空间位阻保护基团，使反应对 oCH 胺化具有选择性。根据密度泛函理论计算，该反应的分子内 Buchwald 偶联经历了脱芳构化和 1,3-钯迁移过程。给出了保护基团控制化学选择性的原因。此外，实现了对 4-哌嗪基吲哚和 GOT1 抑制剂的合成应用。
• [EN] FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS<br/>[FR] INDOLES FONCTIONNALISÉS ET SUBSTITUÉS UTILISÉS EN TANT QU'AGENTS ANTI-CANCÉREUX
  申请人：NOVOGEN LTD

  公开号：WO2015074124A1

  公开（公告）日：2015-05-28

  The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a proliferative disease, preferably cancer, using compounds of the invention.

  本发明涉及抗肌球蛋白化合物，其制备方法，以及利用本发明的化合物治疗或预防增殖性疾病，优选为癌症的方法。
• [EN] SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS<br/>[FR] DÉRIVÉS DE PHÉNOXYPROPYLCYCLOAMINE SUBSTITUÉS EN TANT QUE LIGANDS DE RÉCEPTEUR D'HISTAMINE-3 (H3)
  申请人：CEPHALON INC

  公开号：WO2011002984A1

  公开（公告）日：2011-01-06

  The present invention provides compounds of formula I: their use as H3 antagonists/inverse agonists, processes for their preparation, and pharmaceutical compositions thereof.

  本发明提供了式I的化合物：它们作为H3受体拮抗剂/逆向激动剂的用途，它们的制备方法以及药物组合物。
• Synthesis and characterization of several series of 4-acyl-1-[2-aryl-1-diazenyl]piperazines
  作者：Vanessa Renee Little、Keith Vaughan

  DOI：10.1139/cjc-2014-0242

  日期：2014.9

  Five series of a novel class of 4-acyl-1-[2-aryl-1-diazenyl]piperazines have been synthesized and characterized: the 4-acetyl-1-[2-aryl-1-diazenyl]piperazines [series 1]; the 4-cyclohexylcarbonyl-1-[2-aryl-1-diazenyl]piperazines [series 2]; the 4-benzoyl-1-[2-aryl-1-diazenyl]piperazines [series 3]; the benzyl 4-[2-aryl-1-diazenyl]-1-piperazinecarboxylates [series 4]; and the t-butyl 4-[2-aryl-1-diazenyl]-1-piperazinecarboxylates [series 5]. The compounds were synthesized by diazotization of a primary aromatic amine and subsequent coupling to an appropriate secondary amine: 1-acetylpiperazine [series 1]; 1-(cyclohexylcarbonyl)-piperaizine [series 2]; 1-benzoylpiperazine [series 3]; benzyl 1-piperazinecarboxylate [series 4]; and t-butyl piperazine-1-carboxylate (1-BOC-piperazine) [series 5]. The compounds of series 1–5 were characterized by ¹H NMR, ¹³C NMR, high-resolution MS and IR spectroscopy. The model compounds 1,4-di[2-aryl-1-diazenyl]piperazines, and ethyl 4-[2-aryl-1-diazenyl]-1-piperazinecarboxylates were used to facilitate the assignment of the chemical shifts specific to the piperazine ring carbons. HSQC spectra of select compounds established the correlation between proton and carbon resonance signals.

  一种新型的4-酰基-1-[2-芳基-1-重氮基]哌嗪类化合物的五个系列已经合成并表征：4-乙酰基-1-[2-芳基-1-重氮基]哌嗪 [系列1]；4-环己基甲酰-1-[2-芳基-1-重氮基]哌嗪 [系列2]；4-苯甲酰-1-[2-芳基-1-重氮基]哌嗪 [系列3]；苄基4-[2-芳基-1-重氮基]-1-哌嗪羧酸酯 [系列4]；叔丁基4-[2-芳基-1-重氮基]-1-哌嗪羧酸酯 [系列5]。这些化合物通过对一种主要芳香胺进行重氮化，然后与适当的二级胺偶联而合成：1-乙酰基哌嗪 [系列1]；1-(环己基甲酰)-哌嗪 [系列2]；1-苯甲酰哌嗪 [系列3]；苄基1-哌嗪羧酸酯 [系列4]；叔丁基哌嗪-1-羧酸酯（1-BOC-哌嗪）[系列5]。系列1-5的化合物通过1H NMR、13C NMR、高分辨质谱和红外光谱进行了表征。模型化合物1,4-二[2-芳基-1-重氮基]哌嗪和乙酸乙酯4-[2-芳基-1-重氮基]-1-哌嗪羧酸酯用于帮助确定特定于哌嗪环碳的化学位移的归属。选择性化合物的HSQC谱建立了质子和碳共振信号之间的相关性。

表征谱图